Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2009 18:03 ET | Source: MediciNova, Inc.

MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease

SAN DIEGO, Nov. 3, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
September 16, 2009 06:00 ET | Source: MediciNova, Inc.

MediciNova, Inc. Appoints Mr. Hiroaki Shigeta to Its Board of Directors

SAN DIEGO, Sept. 16, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
September 04, 2009 06:00 ET | Source: MediciNova, Inc.

MediciNova to Present At the Rodman and Renshaw Annual Global Investment Conference

SAN DIEGO, Sept. 4, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
August 21, 2009 06:00 ET | Source: MediciNova, Inc.

MediciNova and Avigen Enter Into Definitive Agreement for Business Combination

SAN DIEGO and ALAMEDA, Calif., Aug. 21, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market...
August 14, 2009 06:10 ET | Source: MediciNova, Inc.

MediciNova Reports Second Quarter 2009 Results

SAN DIEGO, Aug. 14, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
July 20, 2009 17:00 ET | Source: MediciNova, Inc.

MediciNova to Evaluate MN-221 for the Treatment of Chronic Obstructive Pulmonary Disease Exacerbations

SAN DIEGO, July 20, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
July 13, 2009 17:00 ET | Source: MediciNova, Inc.

MediciNova Announces Proposed Final Protocol for Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 in Patients With Severe, Acute Exacerbations of Asthma

SAN DIEGO, July 13, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
June 25, 2009 06:00 ET | Source: MediciNova, Inc.

MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination

SAN DIEGO and ALAMEDA, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market...
June 22, 2009 17:00 ET | Source: MediciNova, Inc.

Arlene Morris Joins MediciNova's Audit Committee

SAN DIEGO, June 22, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
May 28, 2009 17:00 ET | Source: MediciNova, Inc.

MediciNova Announces Plan to Modify Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 in Patients With Severe, Acute Exacerbations of Asthma

SAN DIEGO, May 28, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...